RxDoctor Payments Data

Betsy Thomson

Nurse Practitioner · Salisbury, MDNPI 1104597103

Payments from drug & device makers

$2,976in general payments, 2019–2025

Across 123 payments — averaging $24.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$490
  • Amgen$435
  • Lilly USA, LLC$410
  • Abbott$368
  • Insulet Corporation$311
  • Amneal Pharmaceuticals LLC$222
  • plus $739 from 16 others

What the payments were for

  • Food & beverage$2,964100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,976 in reported general payments places this provider in the 90th percentile of 1,562 nurse practitioner providers in Maryland.

See all nurse practitioner providers in Maryland

Medicare billing

Part B allowed, 2024
$102,343
Medicare patients
361
Services billed
2,439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide319$416,700
OzempicSemaglutide156$228,151
JardianceEmpagliflozin135$160,768
TrulicityDulaglutide80$105,285
JanuviaSitagliptin Phosphate79$84,836
TradjentaLinagliptin38$43,033
Fiasp FlextouchInsulin Aspart (Niacinamide)26$32,739
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog36$31,538
RybelsusSemaglutide21$27,315
Humalog Kwikpen U-100Insulin Lispro61$21,231
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/720$19,695
FarxigaDapagliflozin Propanediol21$18,933
Humulin R U-500 KwikpenInsulin Regular, Human13$16,210
Tresiba Flextouch U-200Insulin Degludec14$15,726
Lantus SolostarInsulin Glargine,hum.Rec.Anlog142$15,233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$410$521,986399 claims
Novo NordiskOzempic, Rybelsus$490$255,465177 claims
Boehringer IngelheimJardiance, Tradjenta$97$203,801173 claims
AstraZenecaFarxiga$160$18,93321 claims
AbbVieSynthroid$21$3,95853 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid$222$2,916194 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,562 nurse practitioner providers in Maryland.

Other nurse practitioner in Salisbury

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →